Citations 1
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510
